tosufloxacin

Subscribe to Selected New Research on tosufloxacin

57 relevant articles (11 outcomes, 9 trials/studies) found for this Bio-Agent

Description: quinolone anti-infective agent; structure given in first source

Also Known As:

7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-(3-aminopyrrolin-1-yl)-1-(2,4-diflurophenyl)-1.4-dihydro-6-fluoro-4-oxo-1,8-napthyridine-3-carboxylic acid; A 60969; A 61827; A-60969; A-61827; A-64730; T 3262; T-3262; tosufloxacin citric anhydride; tosufloxacin tosilate; tosufloxacin, 4-toluene sulfonate

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Quinolines: 58

Quinolones: 969

Fluoroquinolones: 1268

tosufloxacin: 57

Naphthyridines: 1

tosufloxacin: 57

Experts

1.	Matsuzaki, Kaoru: 2 articles (04/2007 - 06/2006)
2.	Kobayashi, Intetsu: 2 articles (04/2007 - 06/2006)
3.	Sato, Yumie: 2 articles (04/2007 - 06/2006)
4.	Hasegawa, Miyuki: 2 articles (04/2007 - 06/2006)
5.	Tazaki, Hiromi: 1 article (07/2007)
6.	Takahama, Hideto: 1 article (07/2007)
7.	Omika, Kaoru: 1 article (04/2007)
8.	Saika, Takeshi: 1 article (06/2006)
9.	Amano, Ayako: 1 article (06/2006)
10.	Kanayama, Akiko: 1 article (06/2006)

Related Diseases

1.	Infection 01/01/1992 - "Efficacy of tosufloxacin in the treatment of experimentally induced intra-abdominal infections in rats." 06/01/2006 - "These results indicate that tosufloxacin has potent antibacterial activity against major organisms isolated from patients with respiratory or otorhinological infections; further, the results of the present study did not differ from those obtained about 10 years ago." 11/01/1997 - "An in-vivo study using a mixed infection with AM-1155- and tosufloxacin-susceptible B" 06/01/2006 - "The minimum inhibitory concentrations (MICs) of tosufloxacin and other fluoroquinolone antimicrobials for Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella (Branhamella) catarrhalis, isolated, between January 2003 and July 2004, from patients suspected of having respiratory or otorhinological infections were determined" 06/01/2006 - "Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory or otorhinological infections: comparison with the results obtained from organisms isolated about 10 years ago." Get all the results and reference details, order at left...
2.	Respiratory Tract Infections (Respiratory Tract Infection) 04/01/2007 - "Since it was approved in 1990, tosufloxacin was considered to be useful as a therapeutic antimicrobial for the treatment of respiratory infections." 04/01/2007 - "These results indicate that tosufloxacin has the potent antibacterial activity against major organisms detected from patients with respiratory infections" 04/01/2007 - "Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections]" 03/01/1992 - "In respiratory tract infections in mice with Staphylococcus aureus Smith, Streptococcus pneumoniae TMS 3, and Klebsiella pneumoniae 3K25, the efficacy of OPC-17116 was generally greater than that of tosufloxacin" 11/01/1997 - "aureus, CS-940 was as active as tosufloxacin, with a MIC90 of 16 microg/ml. The efficacy of CS-940 against murine respiratory infections due to S" Get all the results and reference details, order at left...
3.	Urinary Tract Infections (Urinary Tract Infection) 04/01/1989 - "Clinical efficacy of T-3262, a new quinolone compound, on urinary tract infection in 1988]" 01/01/1992 - "Clinical efficacy of tosufloxacin on the patients with urinary tract infections]" 03/01/1994 - "Study on clinical effects of tosufloxacin (TFLX) and the long-term low dose therapy for the prophylaxis of recurrent urinary tract infection]" 03/01/1994 - "Forty five patients with complicated urinary tract infections were treated with tosufloxacin (TFLX) in the initial antibacterial treatment" 04/01/1989 - "A newly developed quinolone compound, T-3262, was administered in the treatment of 36 cases of urinary tract infection (UTI) between June and August in 1988" Get all the results and reference details, order at left...
4.	Urethritis 09/01/1994 - "Tosufloxacin in the treatment of nongonococcal urethritis, including Chlamydia trachomatis." 09/01/1994 - "Although the number of study patients was small and the follow-up period short, these results indicate that tosufloxacin and doxycycline are equally effective in the treatment of nongonococcal urethritis." 09/01/1994 - "Sixty-three patients with nongonococcal urethritis were enrolled in an open, comparative study and assigned to 14 days of treatment with tosufloxacin 150 mg orally three times daily or doxycycline 100 mg orally twice daily" Get all the results and reference details, order at left...
5.	Prostatitis 07/01/1993 - "Clinical studies of tosufloxacin on chronic bacterial prostatitis]" 07/01/1993 - "In a multicenter trial at 17 institutions, the usefulness of an oral dose of 300 mg of tosufloxacin (TFLX) twice a day for 14 days were assessed in the management of chronic bacterial prostatitis (CBP) diagnosed by Meares and Stamey method" Get all the results and reference details, order at left...
47 Diseases and 57 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Ofloxacin (Levofloxacin)
2.	Ciprofloxacin (Cipro)
3.	tosufloxacin
4.	grepafloxacin (Raxar)
5.	Norfloxacin
6.	Enoxacin (AT 2266)
7.	Doxycycline (Vibramycin)
8.	sparfloxacin (AT 4140)
9.	Fluoroquinolones
10.	trovafloxacin
55 Drugs and Important Bio-Agents and 40 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>